Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis

S Bloom; S Kiilerich; M R Lassen; A Forbes; K Leiper; E Langholz; E J Irvine; C O'Morain; D Lowson; S Orm

doi:10.1111/j.1365-2036.2004.01926.x

Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis

S Bloom, S Kiilerich, M R Lassen, A Forbes, K Leiper, E Langholz, E J Irvine, C O'Morain, D Lowson, S Orm

Research output: Contribution to journal › Article › peer-review

63 Citations (Scopus)

Abstract

Heparin has anti-inflammatory and immunomodulatory activity which may be of therapeutic benefit in the treatment of ulcerative colitis.

Original language	English
Pages (from-to)	871-878
Number of pages	8
Journal	Alimentary Pharmacology and Therapeutics
Volume	19
Issue number	8
DOIs	https://doi.org/10.1111/j.1365-2036.2004.01926.x
Publication status	Published - 15 Apr 2004

Keywords

Adolescent
Adult
Aged
Aged, 80 and over
Colitis, Ulcerative
Double-Blind Method
Female
Fibrinolytic Agents
Heparin, Low-Molecular-Weight
Humans
Male
Middle Aged
Patient Compliance
Prospective Studies
Treatment Outcome

Access to Document

10.1111/j.1365-2036.2004.01926.x

Cite this

@article{9cff4886d1cf4568b9fd9105d4f5b092,

title = "Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis",

abstract = "Heparin has anti-inflammatory and immunomodulatory activity which may be of therapeutic benefit in the treatment of ulcerative colitis.",

keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Colitis, Ulcerative, Double-Blind Method, Female, Fibrinolytic Agents, Heparin, Low-Molecular-Weight, Humans, Male, Middle Aged, Patient Compliance, Prospective Studies, Treatment Outcome",

author = "S Bloom and S Kiilerich and Lassen, {M R} and A Forbes and K Leiper and E Langholz and Irvine, {E J} and C O'Morain and D Lowson and S Orm",

year = "2004",

month = apr,

day = "15",

doi = "10.1111/j.1365-2036.2004.01926.x",

language = "English",

volume = "19",

pages = "871--878",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley",

number = "8",

}

Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. / Bloom, S; Kiilerich, S; Lassen, M R; Forbes, A; Leiper, K; Langholz, E; Irvine, E J; O'Morain, C; Lowson, D; Orm, S.

In: Alimentary Pharmacology and Therapeutics, Vol. 19, No. 8, 15.04.2004, p. 871-878.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis

AU - Bloom, S

AU - Kiilerich, S

AU - Lassen, M R

AU - Forbes, A

AU - Leiper, K

AU - Langholz, E

AU - Irvine, E J

AU - O'Morain, C

AU - Lowson, D

AU - Orm, S

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Heparin has anti-inflammatory and immunomodulatory activity which may be of therapeutic benefit in the treatment of ulcerative colitis.

AB - Heparin has anti-inflammatory and immunomodulatory activity which may be of therapeutic benefit in the treatment of ulcerative colitis.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Colitis, Ulcerative

KW - Double-Blind Method

KW - Female

KW - Fibrinolytic Agents

KW - Heparin, Low-Molecular-Weight

KW - Humans

KW - Male

KW - Middle Aged

KW - Patient Compliance

KW - Prospective Studies

KW - Treatment Outcome

U2 - 10.1111/j.1365-2036.2004.01926.x

DO - 10.1111/j.1365-2036.2004.01926.x

M3 - Article

C2 - 15080848

VL - 19

SP - 871

EP - 878

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 8

ER -